n-hydroxysuccinimide has been researched along with Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, H; Gao, Y; Li, E; Liao, R; Nie, A; Qi, W; Tan, L; Wu, J; Yang, P; Yi, W; Yu, Y; Zheng, D; Zhou, S | 1 |
| Chen, A; Chou, SH; Geng, Y; Morris, T; Munirathinam, G; Pipathsouk, A; Shetty, AV; Tan, I; Wang, B; Xu, L; Zheng, G | 1 |
2 other study(ies) available for n-hydroxysuccinimide and Lymphoma
| Article | Year |
|---|---|
Sensitive and Precise Characterization of Combinatorial Histone Modifications by Selective Derivatization Coupled with RPLC-EThcD-MS/MS.
Topics: Amino Acid Sequence; Chromatography, Reverse-Phase; Histone Code; Histones; Humans; Lymphoma; Peptides; Protein Processing, Post-Translational; Succinimides; Tandem Mass Spectrometry | 2017 |
Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of low systemic toxicity.
Topics: Animals; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphoma; Melanoma, Experimental; Mice; Mice, Transgenic; Palmitic Acid; Recombinant Proteins; Succinimides; T-Lymphocytes, Cytotoxic | 2013 |